# EVerZom

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/everzom

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.everzom.com
- Total disclosed funding: $12M
- Latest round: Series A (Oct 3, 2025)
- Investors on record: 5

## About

EVerZom is a biotechnology company focused on developing exosome-based therapeutics for regenerative medicine, specifically targeting healing processes in digestive and organ tissues. Founded in 2019 and headquartered in Paris, France, EVerZom specializes in exosome technology for regenerative therapies. The founders include Amanda Brun, Jeanne Volatron, and Max Piffoux, with Jeanne Volatron currently serving as CEO. In October 2025, EVerZom raised EUR 10 million in series A funding co-led by new investors Capital Grand Est, European Innovation Council, and Aloe Private Equity, Paris Business Angels and Capital Cell Investors. Other unspecified investors also participated in the round. EVerZom develops innovative exosome-based therapeutics for regenerative medicine, featuring two primary drug candidates. One focuses on healing digestive tissues aimed at Crohn’s fistula, while the other is designed for organ regeneration, specifically for the liver and kidney. The company utilizes its proprietary platform that encompasses exosome generation and formulation, supported by multiple patents. Its products are marketed primarily in Europe, targeting stakeholders in the pharmaceutical industry addressing unmet medical needs.EVerZom generates revenue through partnerships and collaborations with pharmaceutical companies, advancing its therapeutic programs via co-development agreements and potential licensing of its technologies in regenerative medicine. The company’s primary products are in preclinical stages, addressing significant healthcare challenges in digestive and organ injuries. In October 2025, EVerZom raised EUR 10 million in series A funding co-led by new investors Capital Grand Est, European Innovation Council, and Aloe Private Equity, with participation from other new investors Paris Business Angels and Capital Cell Investors. Other unspecified investors also participated in the round. The company will use the October 2025 funding to develop its exosome biotherapies for inflammatory diseases.

## Funding rounds

- Series A, Oct 3, 2025, $12M — Aloe Private Equity, Capital Grand Est, Paris Business Angels, Capital Cell Investors, European Innovation Council

## Investors

- Aloe Private Equity (https://capitalatlas.ai/funds/aloe-private-equity) — Series A
- Capital Grand Est (https://capitalatlas.ai/funds/capital-grand-est) — Series A
- Paris Business Angels (https://capitalatlas.ai/funds/paris-business-angels) — Series A
- Capital Cell Investors — Series A
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series A